MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) and Dyax Corp. (NASDAQ: DYAX) today announced the signing of a licensing agreement covering a broad patent portfolio relating to antibodies and other proteins. The agreement grants MorphoSys a fully paid-up license to a variety of phage display-related patents from Dyax as well as other patents, including several relating to methods for displaying and selecting antibodies and other proteins through the use of alternative types of display. As part of the license agreement, MorphoSys gains the right to sublicense the patents in conjunction with its proprietary technology. The license agreement provides MorphoSys with flexibility for future technology development to further diversify its antibody technology portfolio and improve its offering for therapeutic, diagnostic and research customers. Financial terms were not disclosed.
'We are very pleased about this agreement with Dyax, which provides us even greater flexibility for our future technology development plans,' commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, stated, 'This agreement with MorphoSys recognizes the true value of our intellectual property portfolio as our powerful proprietary display technologies continue to be attractive to many companies in the biotechnology and pharmaceutical industry.' Mr. Blair added, 'We are pleased to have entered into this licensing agreement with MorphoSys.'
For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Public Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com